Pharmaceutical and medical product companies operating in countries of the Eurasian Economic Union (EAEU) will soon be facing a new set of regulations that among other things are intended to establish a single EAEU market with free movement of medicines and medical goods, introduce a new decentralized drug approvals procedure, and help bring down pharmaceutical prices through greater competition.
A key deadline of the new regulatory framework is Dec. 31, 2025, when all medicines will have to be in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?